Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal Deta Chment in Central Serous Chorioretinopathy

Influence of Combined Eplerenone , Intravitreal Aflibercept and Topical Nepafenac Therapy on Serous Foveal Detachment in Central Serous Chorioretinopathy (CSCR)

describing the influence of; combined Eplerenone, intravitreal Aflibercept, and topical Nepafenac; on serous foveal detachment in eyes with CSCR

Retrospective Review of records of eyes with Central serous chorioretinopathy (CSCR) that have been treated in the period between 2015 and 2021

After checking inclusion and exclusion criteria; we will enroll all cases that have been treated by the combination of eplerenone, intravitreal aflibercept and topical nepafenac.

Investigators collected and recorded the following data:

• Age
• Gender
• Systemic hypertension (present or not)
• Smoking (Yes / No)
• Best corrected visual acuity (BCVA) (baseline, final)
• Central macular thickness (CMT) (baseline, final)
• Serous detachment Height (SDH) (baseline, final)
• Duration of Follow-up ( in months)

Inclusion Criteria:

• CSCR eyes treated by combination of Eplerenone, Aflibercept and Nepafenac.

Exclusion Criteria:

• • CSCR treated by other modalities

  • CSCR treated by just 1 or 2 components of :Eplerenone, Aflibercept and Nepafenac